scholarly journals Haemostasis action of VELSEAL-T in a haemophilia A patient with external bleeding

2018 ◽  
Vol 5 (1) ◽  
pp. 4-7
Author(s):  
Anupam Dutta ◽  
Anup Kumar Das
Keyword(s):  
Tranexamic Acid ◽  
Medical Device ◽  
Concrete Surface ◽  
Haemophilia A ◽  
Injury Site ◽  
Safety And Efficacy ◽  
Blood Flows ◽  
Pressure Application ◽  
Rapid Coagulation ◽  
Mild Haemophilia

Abstract VELSEAL-Tis an innovative haemostatic medical device for the control of bleeding. Incorporating a clotting agent (thrombin) and anti-fibrinolytic agent (tranexamic acid), it enables rapid coagulation when blood flows into the dressing, leading to sealing and stabilisation of wound surfaces. A 36-year-old known to have mild haemophilia A presented with profuse bleeding from the forehead after injury following a fall on concrete surface. He attended hospital after 18 hours of injury as bleeding continued as soon as pressure was released from the injury site. A VELSEAL-T patch was applied to the injury site with the patient’s full consent. The bleeding stopped after 60 seconds, but the patient was instructed to hold the patch in place for a further 60 seconds. After two minutes of tight pressure application, there was no more oozing of blood from the injury site. This case shows that VELSEAL-T can be used as an aid in stopping external bleeding in haemophilia patients. Further trials should be undertaken to evaluate the safety and efficacy of this product.

Management of Haemophilia in Sweden

1976 ◽  
Vol 35 (03) ◽  
pp. 510-521 ◽  
Author(s):  
Inga Marie Nilsson
Keyword(s):  
Factor Viii ◽  
Total Population ◽  
Age Groups ◽  
Factor Ix ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Haemophilia B ◽  
Human Fraction ◽  
Mild Haemophilia

SummaryThe incidence of living haemophiliacs in Sweden (total population 8.1 millions) is about 1:15,000 males and about 1:30,000 of the entire population. The number of haemophiliacs born in Sweden in 5-year periods between 1931-1975 (June) has remained almost unchanged. The total number of haemophilia families in Sweden is 284 (77% haemophilia A, 23% haemophilia B) with altogether 557 (436 with A and 121 with B) living haemophiliacs. Of the haemophilia A patients 40 % have severe, 18 % moderate, and 42 % mild, haemophilia. The distribution of the haemophilia B patients is about the same. Inhibitors have been demonstrated in 8% of the patients with severe haemophilia A and in 10% of those with severe haemophilia B.There are 2 main Haemophilia Centres (Stockholm, Malmo) to which haemophiliacs from the whole of Sweden are admitted for diagnosis, follow-up and treatment for severe bleedings, joint defects and surgery. Minor bleedings are treated at local hospitals in cooperation with the Haemophilia Centres. The concentrates available for treatment in haemophilia A are human fraction 1-0 (AHF-Kabi), cryoprecipitate, Antihaemophilic Factor (Hyland 4) and Kryobulin (Immuno, Wien). AHF-Kabi is the most commonly used preparation. The concentrates available for treatment in haemophilia B are Preconativ (Kabi) and Prothromplex (Immuno). Sufficient amounts of concentrates are available. In Sweden 3.2 million units of factor VIII and 1.0 million units of factor IX are given per year. Treatment is free of charge.Only 5 patients receive domiciliary treatment, but since 1958 we in Sweden have practised prophylactic treatment of boys (4–18 years old) with severe haemophilia A. At about 5-10 days interval they receive AHF in amounts sufficient to raise the AHF level to 40–50%. This regimen has reduced severe haemophilia to moderate. The joint score is identical with that found in moderate haemophilia in the same age groups. For treatment of patients with haemophilia A and haemophilia B complicated by inhibitors we have used a large dose of antigen (factor VIII or factor IX) combined with cyclophosphamide. In most cases this treatment produced satisfactory haemostasis for 5 to 30 days and prevented the secondary antibody rise.

Efficiency of Tranexamic Acid in Management of Surgical Orthopedic Bleeding in Patients with Haemophilia

2017 ◽  
Vol 68 (3) ◽  
pp. 627-630 ◽  
Author(s):  
Oana Viola Badulescu ◽  
Razvan Tudor ◽  
Wilhelm Friedl ◽  
Mihaela Blaj ◽  
Paul Dan Sirbu
Keyword(s):  
Tranexamic Acid ◽  
Orthopaedic Surgery ◽  
Enzymatic Degradation ◽  
Point Of View ◽  
Factor Ix ◽  
Haemophilia A ◽  
Chromosome X ◽  
Risk Of Bleeding ◽  
Subchondral Bone Tissue ◽  
Knee Endoprosthesis

Haemophilia is an inherited bleeding disorder (gonosomala recessive, related to chromosome X, with transmission from carrying women to male descendents) characterised from the clinic point of view by important bleeding, secondary to some minimum and biologic traumas by deficiency of trombo-plastino-formation, consecutive to either a deficit of factor VIII (haemophilia A), or the factor IX (haemophilia B). The most characteristic manifestation of hemophilia is intra-articular � hemarthrosis. Its repetitive character leads to irreversible lesions of the articular structures, inducing lesions of the synovium with degenerative effects over the articular cartilage and destructive effects for the subchondral bone tissue. In time, these lesions require orthopaedic surgery to improve the locomotor activity. Managing an efficient hemostasis is vital during surgery, due to high risk of bleeding triggered by coagulopathy and surgery. Numerous studies carried out underlined the efficiency of the tranexamic acid (TXA) in reducing bleeding, in different surgery branches, by inhibiting the enzymatic degradation of fibrin. In orthopaedic surgery, the tranexamic acid is frequently used in case of hip and knee arthroplasties, reducing the bleeding and blood transfusion necessary to the treatment of posthaemorrhagic anemia. This paper wants to assess the efficiency of the tranexamic acid in realization of hemostasis to another category of patients, haemophiliac patients with indication of total hip and knee endoprosthesis.

Mild haemophilia A in Iceland: clinical genetic studies of three families with the same mutation

1994 ◽  
Vol 235 (5) ◽  
pp. 443-450 ◽  
Author(s):  
Ó. JENSSON ◽  
S. STENBJERG BERNVIL ◽  
S. JÖNSÖDTTIR ◽  
J. INGERSLEV
Keyword(s):  
Haemophilia A ◽  
Clinical Genetic ◽  
Genetic Studies ◽  
Mild Haemophilia

scholarly journals Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Haemophilia ◽  
2015 ◽  
Vol 22 (1) ◽  
pp. 72-80 ◽  
Author(s):  
B. Nolan ◽  
J. Mahlangu ◽  
D. Perry ◽  
G. Young ◽  
R. Liesner ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Factor Viii ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Safety And Efficacy ◽  
Fc Fusion Protein

An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A

2013 ◽  
Vol 93 (4) ◽  
pp. 683-692 ◽  
Author(s):  
Catherine J. Rea ◽  
Jonathan H. Foley ◽  
David H. Bevan ◽  
Benny Sørensen
Keyword(s):  
Tranexamic Acid ◽  
Haemophilia A ◽  
In Vitro Assessment

Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements

Haemophilia ◽  
2014 ◽  
Vol 20 (4) ◽  
pp. 550-558 ◽  
Author(s):  
M. Trossaert ◽  
A. Lienhart ◽  
C. Nougier ◽  
M. Fretigny ◽  
M. Sigaud ◽  
...  
Keyword(s):  
Haemophilia A ◽  
Diagnosis And Management ◽  
Mild Haemophilia

scholarly journals Safety and Efficacy of Caproamin Fides and Tranexamic Acid Versus Placebo in Patients Undergoing Coronary Artery Revascularization

2014 ◽  
Vol 6 (3) ◽  
pp. 197-202 ◽  
Author(s):  
Alireza Alizadeh Ghavidel ◽  
Ziae Totonchi ◽  
Mitra Chitsazan ◽  
Maziar Gholampour Dehaki ◽  
Farshid Jalili ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Tranexamic Acid ◽  
Safety And Efficacy ◽  
Coronary Artery Revascularization ◽  
Acid Versus
Sign in / Sign up

Export Citation Format

Share Document